The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells

Anti-Cancer Drugs

Volumn 20, Issue 1, 2009, Pages 21-31

  Huq, Anja ^a,b   Singh, Baljit ^a,b   Meeker, Thea ^b   Mascarenhas, Desmond ^a,b  

^a Mayflower Organization for Research and Education   (United States)

^b Protigen Inc   (United States)

Author keywords

5 fluorouracil insulin like growth factor binding protein 3; Biological modifiers; Chemosensitizer; Mechanistic specificity; Metal binding domain; Metastasis; Peptide therapeutic; Systemic disease

Indexed keywords

FLUOROURACIL; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDE DERIVATIVE; SOMATOMEDIN BINDING PROTEIN 3;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HUMAN CELL; METAL BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL SURVIVAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RATS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57349189384     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283144610     Document Type: Article

References (40)

1. Nylandsted J, Brand K, Jaattela M. Heat shock protein 70 is required for the survival of cancer cells. Ann N Y Acad Sci 2000; 926:122-125.
2. Nylandsted J, Wick W, Hirt UA, Brand K, Rohde M, Leist M, et al. Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion. Cancer Res 2002; 62:7139-7142.
3. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339:974-984.
4. Chong YP, Mulhern TD, Cheng HC. C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK) - endogenous negative regulators of Src-family protein kinases. Growth Factors 2005; 23:233-244.
5. Rao RD, Mladek AC, Lamont JD, Goble JM, Erlichman C, James CD, Sarkaria JN. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 2005; 7:921-929.
6. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11:77-84.
7. Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 1993; 85:570-574.
8. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000; 60:7099-7105.
9. Strik HM, Weller M, Frank B, Hermisson M, Deininger MH, Dichgans J, et al. Heat shock protein expression in human gliomas. Anticancer Res 2000; 20:4457-4462.
10. Ricaniadis N, Kataki A, Agnantis N, Androulakis G, Karakousis CP. Longterm prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Eur J Surg Oncol 2001; 27:88-93.
11. Ciocca DR, Vargas-Roig LM. Hsp27 as a prognostic and predictive factor in cancer. Prog Mol Subcell Biol 2002; 28:205-218.
12. Li GC, Hahn GM. Interactions of hyperthermia and drugs: treatments and probes. Natl Cancer Inst Monogr 1982; 61:317-323.
13. Volloch V, Sherman MY. Oncogenic properties of Hsp72. Oncogene 1999; 18:3648-3651.
14. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995; 270:14255-14258.
15. May MJ, D'Acquisto F, Madge LA, Glöckner J, Pober JS, Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000; 289:1550-1554.
16. Njemini Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:917-921.
17. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1:461-466.
18. Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT, Lane DP. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 2000; 19:2312-2323.
19. Zhang R, Mayhood T, Lipari P, Wang Y, Durkin J, Syto R, et al. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction. Anal Biochem 2004; 331:138-146.
20. Singh BK, Charkowicz DA, Mascarenhas DD. IGF-independent effects mediated by a C-terminal metal-binding domain of insulin-like growth factor binding protein-3. J Biol Chem 2004; 279:477-487.
21. Chicha L, Tussiwand R, Traggiai E, Mazzucchelli L, Bronz L, Piffaretti JC, et al. Human adaptive immune system Rag2-1-gamma(c)-1- mice. Ann N Y Acad Sci 2005; 1044:236-243.
22. Matsuda H, Seo Y, Kakizaki E, Kozawa S, Muraoka E, Yukawa N. Identification of DNA of human origin based on amplification of humanspecific mitochondrial cytochrome region. Forensic Sci Int 2004; 152:109-114.
23. Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, Koniaris LG. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 2005; 23:543-548.
24. Cheung PK, Woolcock B, Adomat H, Sutcliffe M, Bainbridge TC, Jones EC, et al. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res 2004; 64:5929-5933.
25. De Lord C, Clutterbuck R, Titley J, Ormerod M, Gordon-Smith T, Millar J, et al. Growth of primary human acute leukemia in severe combined immunodeficient mice. Exp Hematol 1991; 19:991-993.
26. Paine-Murrieta GD, Taylor CW, Curtis RA, Lopez MHA, Dorr RT, Johnson CS, et al. Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol 1997; 40:209-214.
27. Whenham N, D'Hondt V, Piccart MJ. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer 2008; 8:38-49.
28. Aramburu J, Yaffe MB, López-Rodriguez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 1999; 285:2129-2133.
29. Takayanagi H, Juji T, Miyazaki T, lizuka H, Takahashi T, Isshiki M, et al. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest 1999; 104:137-146.
30. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2: fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994; 9:2523-2529.
31. Sun C, Nettesheim D, Liu Z, Olejniczak ET. Solution structure of human survivin and its binding interface with Smac/Diablo. Biochemistry 2005; 44:11-17.
32. Ron D, Luo J, Mochly-Rosen D. C2 region-derived peptides inhibit translocation and function of beta protein kinase C in vivo. J Biol Chem 1995; 270:24180-24187.
33. Barsyte-Lovejoy D, Galanis A, Sharrocks AD. Specificity determinants in MAPK signaling to transcription factors. J Biol Chem 2002; 277: 9896-9903.
34. Ling Y, Maile LA, Badley-Clarke J, Clemmons DR. DOK1 mediates SHP-2 binding to the alphaVbeta3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells. J Biol Chem 2005; 280:3151-3158.
35. Tai U, McFall SM, Huang K, Demeler B, Fox SG, Brubaker K, et al. Structure-function analysis of the heat shock factor-binding protein reveals a protein composed solely of a highly conserved and dynamic coiled-coil trimerization domain. J Biol Chem 2002; 277:735-745.
36. Moreau JE, Anderson K, Mauney JR, Nguyen T, Kaplan DL, Rosenblatt M. Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res 2007; 67:10304-10308.
37. Smid M, Wang Y, Klijn JGM, Sieuwerts AM, Zhang Y, Atkins D, et al. Genes associated with breast cancer metastasizing to bone. J Clin Oncol 2006; 24:2261-2267.
38. Curran S, Murray Gl. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189:300-308.
39. Fong YC, Maa MC, Tsai FJ, Chen WC, Lin JG, Jeng LB, et al. Osteoblastderived TGF-beta1 stimulates IL-8 release via AP-1 and NF-kappaB in human cancer cells. J Bone Miner Res 2008; 23:961-970.
40. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1989; 8:98-101.